CarnoSyn® 4X Launches with Fourfold Bioavailability Increase
- Bioavailability Boost: CarnoSyn® 4X's proprietary formulation delivers over four times the bioavailability of standard beta-alanine without the associated paresthesia, significantly enhancing user experience in sports nutrition and potentially attracting a broader consumer base.
- Market Expansion Potential: This innovation provides sports nutrition brands with a new way to deliver CarnoSyn® benefits more efficiently, lowering cost-in-use and facilitating product line extensions and new launches.
- Clinical Support Advantage: Backed by over 55 clinical studies, CarnoSyn® 4X maintains its status as the only beta-alanine with New Dietary Ingredient (NDI) status, reinforcing the brand's credibility in the sports nutrition market.
- Brand Trust Continuation: NAI President Kenneth Wolf stated that CarnoSyn® 4X represents the next evolution of the brand in sports nutrition, aiming to attract consumers who may have avoided beta-alanine due to tingling sensations, thereby further solidifying CarnoSyn® as a trusted performance signal.
Trade with 70% Backtested Accuracy
Analyst Views on NAII
About NAII
About the author
CarnoSyn® 4X Launches with Fourfold Bioavailability Increase
- Bioavailability Boost: CarnoSyn® 4X's proprietary formulation delivers over four times the bioavailability of standard beta-alanine without the associated paresthesia, significantly enhancing user experience in sports nutrition and potentially attracting a broader consumer base.
- Market Expansion Potential: This innovation provides sports nutrition brands with a new way to deliver CarnoSyn® benefits more efficiently, lowering cost-in-use and facilitating product line extensions and new launches.
- Clinical Support Advantage: Backed by over 55 clinical studies, CarnoSyn® 4X maintains its status as the only beta-alanine with New Dietary Ingredient (NDI) status, reinforcing the brand's credibility in the sports nutrition market.
- Brand Trust Continuation: NAI President Kenneth Wolf stated that CarnoSyn® 4X represents the next evolution of the brand in sports nutrition, aiming to attract consumers who may have avoided beta-alanine due to tingling sensations, thereby further solidifying CarnoSyn® as a trusted performance signal.
Natural Alternatives International, Inc. Reports Q4 and Year-to-Date Results for Fiscal Year 2025
Financial Performance: Natural Alternatives International, Inc. reported a net loss of $7.2 million for Q4 FY 2025, compared to a loss of $1.9 million in the same quarter of the previous year, with net sales increasing by 15% to $33.9 million.
Annual Overview: For the fiscal year 2025, the company experienced a net loss of $13.6 million, up from $7.2 million in FY 2024, despite a 14% increase in annual net sales to $129.9 million.
Future Outlook: The company anticipates a net loss in the first half of FY 2026 but expects to achieve profitability in the second half, driven by growth in customer relationships and sales.
Operational Challenges: The net loss was attributed to underutilization of factory capacity, a valuation allowance against deferred tax assets, and litigation settlement costs, despite overall revenue growth.
Natural Alternatives International, Inc. Announces New Manufacturing Agreement with The Juice Plus+® Company
Partnership Extension: Natural Alternatives International, Inc. has extended its partnership with The Juice Plus+ Company through a new multi-year Manufacturing Agreement for their capsule and powder products sold globally.
Commitment to Quality: Both companies emphasize their long-standing relationship and commitment to delivering high-quality nutritional products backed by scientific research, aiming for mutual benefits from the contract extension.
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
Financial Performance: Natural Alternatives International, Inc. reported a net loss of $2.2 million for Q3 2025, despite a 14% increase in net sales to $28.8 million compared to the previous year, largely due to increased private-label contract manufacturing sales.
Operational Challenges: The company continues to face operational losses attributed to underutilization of factory capacities, decreased beta-alanine revenue, and rising operating expenses, while maintaining a cautious outlook on profitability for the upcoming fiscal year.
Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination
Clinical Trial Results: Natural Alternatives International, Inc. announced that their TriBsyn™ beta-alanine complex significantly increases bioavailability and efficiency while eliminating the common side effect of paresthesia, as published in the journal Food Hydrocolloids for Health.
Product Innovation: TriBsyn™, utilizing proprietary Hydro Oleo technology, offers a higher potency and better absorption of beta-alanine, making it suitable for active aging populations and those seeking enhanced muscle vitality and cognitive performance without discomfort.
CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients
New Distribution Partnership: Natural Alternatives International, Inc. has partnered with B&D Nutritional Ingredients to distribute its new carnosine booster, TriBsyn™, targeting the U.S. dietary supplement market.
Product Benefits: TriBsyn™ is designed to enhance beta-alanine absorption without causing the typical paresthesia sensation, aiming to benefit various consumer groups including older adults and those seeking cognitive and physical health support.
CarnoSyn® 4X Launches with Fourfold Bioavailability Increase
- Bioavailability Boost: CarnoSyn® 4X's proprietary formulation delivers over four times the bioavailability of standard beta-alanine without the associated paresthesia, significantly enhancing user experience in sports nutrition and potentially attracting a broader consumer base.
- Market Expansion Potential: This innovation provides sports nutrition brands with a new way to deliver CarnoSyn® benefits more efficiently, lowering cost-in-use and facilitating product line extensions and new launches.
- Clinical Support Advantage: Backed by over 55 clinical studies, CarnoSyn® 4X maintains its status as the only beta-alanine with New Dietary Ingredient (NDI) status, reinforcing the brand's credibility in the sports nutrition market.
- Brand Trust Continuation: NAI President Kenneth Wolf stated that CarnoSyn® 4X represents the next evolution of the brand in sports nutrition, aiming to attract consumers who may have avoided beta-alanine due to tingling sensations, thereby further solidifying CarnoSyn® as a trusted performance signal.
Natural Alternatives International, Inc. Reports Q4 and Year-to-Date Results for Fiscal Year 2025
Financial Performance: Natural Alternatives International, Inc. reported a net loss of $7.2 million for Q4 FY 2025, compared to a loss of $1.9 million in the same quarter of the previous year, with net sales increasing by 15% to $33.9 million.
Annual Overview: For the fiscal year 2025, the company experienced a net loss of $13.6 million, up from $7.2 million in FY 2024, despite a 14% increase in annual net sales to $129.9 million.
Future Outlook: The company anticipates a net loss in the first half of FY 2026 but expects to achieve profitability in the second half, driven by growth in customer relationships and sales.
Operational Challenges: The net loss was attributed to underutilization of factory capacity, a valuation allowance against deferred tax assets, and litigation settlement costs, despite overall revenue growth.
Natural Alternatives International, Inc. Announces New Manufacturing Agreement with The Juice Plus+® Company
Partnership Extension: Natural Alternatives International, Inc. has extended its partnership with The Juice Plus+ Company through a new multi-year Manufacturing Agreement for their capsule and powder products sold globally.
Commitment to Quality: Both companies emphasize their long-standing relationship and commitment to delivering high-quality nutritional products backed by scientific research, aiming for mutual benefits from the contract extension.
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
Financial Performance: Natural Alternatives International, Inc. reported a net loss of $2.2 million for Q3 2025, despite a 14% increase in net sales to $28.8 million compared to the previous year, largely due to increased private-label contract manufacturing sales.
Operational Challenges: The company continues to face operational losses attributed to underutilization of factory capacities, decreased beta-alanine revenue, and rising operating expenses, while maintaining a cautious outlook on profitability for the upcoming fiscal year.
Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination
Clinical Trial Results: Natural Alternatives International, Inc. announced that their TriBsyn™ beta-alanine complex significantly increases bioavailability and efficiency while eliminating the common side effect of paresthesia, as published in the journal Food Hydrocolloids for Health.
Product Innovation: TriBsyn™, utilizing proprietary Hydro Oleo technology, offers a higher potency and better absorption of beta-alanine, making it suitable for active aging populations and those seeking enhanced muscle vitality and cognitive performance without discomfort.
CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients
New Distribution Partnership: Natural Alternatives International, Inc. has partnered with B&D Nutritional Ingredients to distribute its new carnosine booster, TriBsyn™, targeting the U.S. dietary supplement market.
Product Benefits: TriBsyn™ is designed to enhance beta-alanine absorption without causing the typical paresthesia sensation, aiming to benefit various consumer groups including older adults and those seeking cognitive and physical health support.
